Propel Bio Management LLC Has $5.95 Million Stock Holdings in Compass Pathways PLC Sponsored ADR $CMPS

Propel Bio Management LLC raised its holdings in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 69.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 861,778 shares of the company’s stock after purchasing an additional 351,778 shares during the period. Compass Pathways makes up about 5.1% of Propel Bio Management LLC’s portfolio, making the stock its 7th largest holding. Propel Bio Management LLC owned approximately 0.90% of Compass Pathways worth $5,946,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Advisory Services Network LLC acquired a new position in shares of Compass Pathways in the 3rd quarter valued at approximately $41,000. BIT Capital GmbH acquired a new position in shares of Compass Pathways in the 3rd quarter valued at approximately $54,000. Northeast Financial Consultants Inc acquired a new position in shares of Compass Pathways in the 2nd quarter valued at approximately $59,000. Raymond James Financial Inc. raised its position in shares of Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after buying an additional 6,228 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC acquired a new position in shares of Compass Pathways in the 4th quarter valued at approximately $104,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Trading Down 7.2%

Shares of Compass Pathways stock opened at $12.11 on Friday. The firm’s 50 day moving average is $8.99 and its 200 day moving average is $7.39. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $14.76. The firm has a market capitalization of $1.63 billion, a PE ratio of -3.84 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. Equities research analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Compass Pathways in a research report on Wednesday, May 13th. B. Riley Financial assumed coverage on shares of Compass Pathways in a research report on Friday, April 24th. They issued a “buy” rating and a $17.00 target price for the company. HC Wainwright restated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Morgan Stanley boosted their target price on shares of Compass Pathways from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Finally, Jefferies Financial Group upgraded shares of Compass Pathways to a “strong-buy” rating in a research report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.36.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.